Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9026)	11/21/2005 1:52:24 PM
From: quidditch	Respond to of 10280

I was traveling on b, stressed out, and underslept, so I provisioned for some L to take some of the edge off and try to restore some Z's equilibrium to this weathered body and soul. I was a little nervous about not having the oj to take the small white tablet. 1st night--seven solid hours of deep sleep (with some very pleasant dreams I hadn't revisited in a while (:-) disturbed only by the alarm 2nd night--five solid hours Metallic taste? I have a sensitive palate and am a foodie, so I was expecting the worst, like chewing vigorously on a mouth stuffed with aluminum foil. Result: a faint, back of the mouth metallic taste/feel--barely worth recounting. I think this is way over done courtesy of the Ambien and PFE crowd. quid

To: Biomaven who wrote (9026)	11/21/2005 2:14:14 PM
From: Biomaven	Respond to of 10280

The closest in size to Lunesta I see in the numbers I have is Advair, which had scripts of 125k in week 32 after launch. At 52 weeks Advair scripts were 183k, and at 76 weeks (latest I have) they were 209k. (Advair is cyclical though, being an asthma drug, and I don't know at what point in the year it was launched.) Nexium was 137k at 32 weeks, 237k at 52 weeks and 302k at 78 weeks. So those two examples indicate that a doubling in sales a year from this point in a launch is not out of the question. Peter